 YONKERS, N.Y., June 17, 2021 GLOBE NEWSWIRE -- ContraFect Corporation Nasdaq: CFRX, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced multiple presentations, including two oral presentations, of data from its portfolio of DLAs at the 2021 World Microbe Forum, being held virtually from June 20-24, 2021. 